EquityFlowCompanies › InProTher

InProTher

Biotech · Copenhagen, DK

Immuno-oncology targeting Human Endogenous Retroviruses (HERVs)

Funding history

DateRoundAmount
May 2023Seed
Copenhagen biotech InProTher raised EUR6M seed for its HERV-targeting cancer immunotherapy.
$6.5M

Investors

European Innovation Council Fund

Similar companies in Biotech

Explore funding flow on EquityFlow →